Adenosine [58-61-7]

Cat# HY-B0228-500mg

Size : 500mg

Brand : MedChemExpress

Adenosine [58-61-7]
Description

Adenosine (Adenine riboside), a ubiquitous and BBB-permeable endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2].

IC50 & Target

Human Endogenous Metabolite

 

Microbial Metabolite

 

Cellular Effect
Cell Line Type Value Description References
A-431 IC50
195 μM
Compound: Adenosine
Inhibition of erbB-1 receptor tyrosine kinase from A431 human epidermoid carcinoma cells
Inhibition of erbB-1 receptor tyrosine kinase from A431 human epidermoid carcinoma cells
[PMID: 9089334]
CHO EC50
0.29 μM
Compound: adenosine
Agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as increase of intracellular calcium level
Agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as increase of intracellular calcium level
[PMID: 20541935]
CHO EC50
0.29 μM
Compound: adenosine
Agonist activity at human adenosine A3 receptor expressed in CHO cells
Agonist activity at human adenosine A3 receptor expressed in CHO cells
[PMID: 21388809]
CHO EC50
0.31 μM
Compound: adenosine
Agonist activity at human adenosine A1 receptor expressed in CHO cells assessed as increase of intracellular calcium level
Agonist activity at human adenosine A1 receptor expressed in CHO cells assessed as increase of intracellular calcium level
[PMID: 20541935]
CHO EC50
0.31 μM
Compound: adenosine
Agonist activity at human adenosine A1 receptor expressed in CHO cells
Agonist activity at human adenosine A1 receptor expressed in CHO cells
[PMID: 21388809]
CHO EC50
0.7 μM
Compound: adenosine
Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as increase of intracellular calcium level
Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as increase of intracellular calcium level
[PMID: 20541935]
CHO EC50
0.7 μM
Compound: adenosine
Agonist activity at human adenosine A2A receptor expressed in CHO cells
Agonist activity at human adenosine A2A receptor expressed in CHO cells
[PMID: 21388809]
CHO EC50
23500 nM
Compound: AR-1
Agonist activity at human adenosine A2B receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
Agonist activity at human adenosine A2B receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
[PMID: 26356532]
CHO EC50
24 μM
Compound: adenosine
Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as increase of intracellular calcium level
Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as increase of intracellular calcium level
[PMID: 20541935]
CHO EC50
24 μM
Compound: adenosine
Agonist activity at human adenosine A2B receptor expressed in CHO cells
Agonist activity at human adenosine A2B receptor expressed in CHO cells
[PMID: 21388809]
CHO EC50
290 nM
Compound: AR-1
Agonist activity at human adenosine A3 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
Agonist activity at human adenosine A3 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
[PMID: 26356532]
CHO EC50
310 nM
Compound: AR-1
Agonist activity at human adenosine A1 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
Agonist activity at human adenosine A1 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
[PMID: 26356532]
CHO EC50
730 nM
Compound: AR-1
Agonist activity at human adenosine A2A receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
Agonist activity at human adenosine A2A receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
[PMID: 26356532]
COS-7 EC50
1.04 μM
Compound: adenosine
Activity against human wild type adenosine A3 receptor expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay
Activity against human wild type adenosine A3 receptor expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay
[PMID: 16640329]
Detroit 98 ED50
0.08 μM
Compound: 2
Concentration that inhibited the growth of cultured human detroit 98 cells.
Concentration that inhibited the growth of cultured human detroit 98 cells.
[PMID: 7131482]
HEK-293T EC50
0.039 μM
Compound: Adenosine
Agonist activity at human A1AR expressed in HEK293T/17 cells assessed as inhibition of isoproterenol-induced cAMP accumulation incubated for 10 mins by luciferase reporter assay
Agonist activity at human A1AR expressed in HEK293T/17 cells assessed as inhibition of isoproterenol-induced cAMP accumulation incubated for 10 mins by luciferase reporter assay
[PMID: 22738238]
HeLa IC50
10.8 μM
Compound: 37
Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture.
Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture.
[PMID: 7473592]
HeLa IC50
98.85 μM
Compound: 37
Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet.
Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet.
[PMID: 7473592]
HEp-2 IC50
0.7 μM
Compound: 1
Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control.
Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control.
[PMID: 6708054]
HEp-2 IC50
20 μM
Compound: 1
Compound was evaluated for cytotoxicity against H.Ep.-2 (AK-) cells and concentration required to inhibit the growth of treated cells to 50% of untreated control
Compound was evaluated for cytotoxicity against H.Ep.-2 (AK-) cells and concentration required to inhibit the growth of treated cells to 50% of untreated control
[PMID: 6708054]
HepG2 IC50
18.46 μM
Compound: 35
Inhibition of PCSK9 mRNA expression in human HepG2 cells by SYBR Green I dye-based qRT-PCR analysis
Inhibition of PCSK9 mRNA expression in human HepG2 cells by SYBR Green I dye-based qRT-PCR analysis
[PMID: 30448414]
L1210 EC50
1.869 mM
Compound: 2
Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs
Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs
[PMID: 24915876]
L1210 IC50
0.991 mM
Compound: 2
Cytotoxicity against mouse L1210 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
Cytotoxicity against mouse L1210 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
[PMID: 24915876]
L929 ED50
0.3 μM
Compound: 2
Concentration that inhibited the growth of Mouse L cells.
Concentration that inhibited the growth of Mouse L cells.
[PMID: 7131482]
PBMC IC50
1.867 mM
Compound: 2
Cytotoxicity against human PBMC assessed as inhibition of cell viability after 72 hrs by MTT assay
Cytotoxicity against human PBMC assessed as inhibition of cell viability after 72 hrs by MTT assay
[PMID: 24915876]
RAW264.7 IC50
>10 μM
Compound: 19
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
[PMID: 28499733]
U2OS EC50
63 μM
Compound: 60961
Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay (PubChem AID: 1745861)
Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay (PubChem AID: 1745861)
[PMID: 31551431]
In Vitro

Adenosine (Adenine riboside) acts on four G-protein coupled receptors: two of them, A1 and A3, are primarily coupled to Gi family G proteins; and two of them, A2A and A2B, are mostly coupled to Gs like G proteins. These receptors are antagonized by xanthines including caffeine. Via these receptors it affects many cells and organs, usually having a cytoprotective function[2].
Adenosine is an extracellular signaling molecule that is generated from its precursor molecules 5’-adenosine triphosphate (ATP) and 5’-adenosine monophosphate (AMP)[3].
Adenosine is a common metabolite of ATP, which exhibits cytotoxic effects at high concentrations.Adenosine (1.0-4.0 mM; 12-24 hours) inhibits cell viability and triggers ER stress in HepG2 cells[4].
Adenosine induces apoptosis in a variety of cancer cells. Adenosine (2.0 mM; 12-24 hours) induces autophagy in HepG2 cells. In HepG2 cell lines, Adenosine -induced AMPK/mTOR pathway activation partially blocked ER stress and decreased apoptotic cell death[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvent & Solubility
In Vitro: 

DMSO : 33.33 mg/mL (124.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 5 mg/mL (18.71 mM; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7418 mL 18.7091 mL 37.4181 mL
5 mM 0.7484 mL 3.7418 mL 7.4836 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 6.67 mg/mL (24.96 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
HY-10227-10mg
 10mg 
HY-16637-500mg
 500mg 
HY-N0326-500mg
 500mg